Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trialSteven M. Horwitz, June Weon Cheong, Owen A. O’Connor et al.|The Lancet|2018Cited by 733
Sirolimus Plus MEC Chemotherapy Has Significant Activity in High Risk AML Patients Especially Those Who Exhibit in Vivo Inhibition of the mTOR PathwayMargaret Kasner, Alexander E. Perl, Alison W. Loren et al.|Blood|2012Cited by 3